efprezimod alfa

Efprezimod alfa is a recombinant fusion protein composed of the extracellular domain of mature human glycoprotein CD24 linked to a human immunoglobulin G1 (IgG1) Fc domain. It was originally developed as an immunomodulator for the prevention and treatment of graft-versus-host disease in stem cell transplantation, with further investigation in autoimmune disorders, COVID‑19, dyslipidemias, and solid tumors. The drug acts by binding to danger-associated molecular patterns (DAMPs), preventing their interaction with toll-like receptors (TLRs), thereby inhibiting nuclear factor-kappa B (NFkB) activation and secretion of inflammatory cytokines. Efprezimod alfa also binds to and activates Siglec G/10 (the mouse/human homologs), stimulating SHP‑1-mediated inhibitory signaling that further suppresses inflammatory responses. This mechanism positions efprezimod alfa as an immune checkpoint inhibitor targeting innate immune activation pathways[1][3][5].

Brand names

SACCOVID

Other names

Human CD24 and human IgG Fc Fusion Protein